Abstract
Mutational models denoting KEAP1-NRF2 pathway activation have emerged as determinants of survival outcomes in non-small cell lung cancer (NSCLC). Hypothesizing that genetically distinct tumors recapitulate the transcriptional footprint of KEAP1 mutations (KEAPness), we identified a KEAP1-NRF2-related gene set shared by tumors with and without pathway mutations. KEAPness-dominant tumors were associated with poor survival outcomes and immune exclusion in two independent cohorts of immunotherapy-treated NSCLC (SU2C and OAK/POPLAR). Moreover, patients with KEAPness tumors had survival outcomes comparable to their KEAP1-mutant counterparts. In the TRACERx421, KEAPness exhibited limited transcriptional intratumoral heterogeneity and an immune-excluded microenvironment, as highlighted by orthogonal methods for T cell estimation. This phenotypic state widely occurred across genetically divergent tumors, exhibiting shared and private cancer genes under positive selection when compared to KEAP1-mutant tumors. Collectively, we discovered the pervasive nature of the KEAPness phenotypic driver across evolutionary divergent tumors. This model outperforms mutation-based classifiers in predicting survival outcomes.
Competing Interest Statement
R.D.M. reports serving as a scientific advisory board member at Exosomics SpA (Siena IT), HiberCell Inc. (New York, NY), Kiromic Inc. (Houston, TX) and Exiris Inc. (Rome, IT). FC reports personal fees from Roche/Genentech, AstraZeneca, Takeda, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, and Bayer. M.M.A. reported serving as a consultant for Achilles, AbbVie, Neon, Maverick, Nektar, and Hegrui; receiving grants and personal fees from Genentech, Bristol-Myers Squibb, Merck, AstraZeneca, and Lilly; and receiving personal fees from Maverick, Blueprint Medicine, Syndax, Ariad, Nektar, Gritstone, ArcherDx, Mirati, NextCure, Novartis, EMD Serono, and NovaRx. N.M. has received consultancy fees and has stock options in Achilles Therapeutics. He holds European patents relating to targeting neoantigens (PCT/EP2016/ 059401), identifying clinical response to immune checkpoint blockade (PCT/ EP2016/071471), determining HLA loss of heterozygosity (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). The remaining authors declare no conflict of interest. M.J.-H. has consulted for, and is a member of, the Achilles Therapeutics Scientific Advisory Board and Steering Committee; has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster and Bristol Myers Squibb and is listed as a co-inventor on a European patent application relating to methods to detect lung cancer (PCT/US2017/028013). This patent has been licensed to commercial entities and, under terms of employment, M.J.-H. is due a share of any revenue generated from such license(s).
Funding Statement
M. Maugeri-Sacca' is supported by by the Italian Association for Cancer Research (AIRC) under MFAG 2019 - project ID. 22940, and the Italian Ministry of Health (MoH)- project ID. GR-2016-02362025.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
WES and RNA-Seq data related to the TCGA NSCLC study are freely available at https://www.cbioportal.org/. Details regarding data availability of the SU2C cohort are provided in the original publication (Ravi, A. et al. Nat Genet. 55, 807-819, 2023). Data related to the OAK/POPLAR trials are deposited to the European Genome-phenome Archive (EGA) (Study ID EGAS00001005013. Datasets: EGAD00001007703, EGAD00001008550, EGAD00001008390, EGAD00001008391, EGAD00001008548, EGAD00001008549). TRACERx 421 data are available from the original publication (Martinez-Ruiz, C. Nature. 616, 543-552, 2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* These authors share senior authorship.
The manuscript has been improved compared with the previous version. Pan-cancer-level analyses have been added that strengthen relevance of findings. As a result, some figures have been modified.
Data Availability
All data produced in the present work are contained in the manuscript